与茚地那韦、利托那韦和/或沙奎那韦选择的蛋白酶抑制剂交叉耐药相关的1型人类免疫缺陷病毒蛋白酶切割位点突变。
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
作者信息
Côté H C, Brumme Z L, Harrigan P R
机构信息
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada V6Z 1Y6.
出版信息
J Virol. 2001 Jan;75(2):589-94. doi: 10.1128/JVI.75.2.589-594.2001.
Abstract
We examined the prevalence of cleavage site mutations, both within and outside the gag region, in 28 protease inhibitor (PI) cross-resistant patients treated with indinavir, ritonavir, and/or saquinavir compared to control patients treated with reverse transcriptase inhibitors. Three human immunodeficiency virus protease cleavage sites within gag (p2/NC, NC/p1, and NC/TFP) showed considerable in vivo evolution before and after therapy with indinavir, ritonavir, and/or saquinavir. Another gag cleavage site (p1/p6(gag)) showed a trend compared to matched controls. The other eight recognized cleavage sites showed relatively little difference between PI-resistant cases and controls. An A-->V substitution at the P2 position of the NC/p1 and NC/TFP cleavage sites was the most common (29%) change selected by the PIs used in this study.
摘要
我们检测了28例接受茚地那韦、利托那韦和/或沙奎那韦治疗的蛋白酶抑制剂（PI）交叉耐药患者与接受逆转录酶抑制剂治疗的对照患者中，gag区域内外切割位点突变的发生率。gag区域内的三个人类免疫缺陷病毒蛋白酶切割位点（p2/NC、NC/p1和NC/TFP）在接受茚地那韦、利托那韦和/或沙奎那韦治疗前后显示出相当程度的体内进化。另一个gag切割位点（p1/p6(gag)）与匹配的对照组相比呈现出一种趋势。其他八个公认的切割位点在PI耐药病例和对照组之间差异相对较小。NC/p1和NC/TFP切割位点P2位置的A→V替换是本研究中使用的PI选择的最常见（29%）变化。
相似文献
1
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.与茚地那韦、利托那韦和/或沙奎那韦选择的蛋白酶抑制剂交叉耐药相关的1型人类免疫缺陷病毒蛋白酶切割位点突变。
J Virol. 2001 Jan;75(2):589-94. doi: 10.1128/JVI.75.2.589-594.2001.
2
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.HIV-1 治疗患者中 Gag 裂解位点与蛋白酶突变及病毒学反应的关联
J Infect. 2007 Apr;54(4):367-74. doi: 10.1016/j.jinf.2006.06.012. Epub 2006 Jul 26.
3
Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.在接受过蛋白酶抑制剂治疗、感染1型人类免疫缺陷病毒且基于洛匹那韦和利托那韦的治疗失败的受试者中耐药性的选择：突变模式及基线相关性
J Virol. 2005 Mar;79(6):3329-38. doi: 10.1128/JVI.79.6.3329-3338.2005.
4
[Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].[感染HIV-1患者的蛋白酶基因多态性及对包括蛋白酶抑制剂在内的治疗的反应]
Pathol Biol (Paris). 1999 May;47(5):549-52.
5
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.1型人类免疫缺陷病毒蛋白酶、逆转录酶、切割位点及p6突变对沙奎那韦、利托那韦与两种核苷类似物四联疗法病毒学应答的影响
AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):487-97. doi: 10.1089/08892220151126526.
6
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.在基于奈非那韦和洛匹那韦/利托那韦的治疗出现病毒学失败后，HIV-1蛋白酶中的突变模式及相关氨基酸替换
J Med Virol. 2007 Nov;79(11):1617-28. doi: 10.1002/jmv.20986.
7
Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.人类免疫缺陷病毒1型感染的母婴中，HIV-1蛋白酶、Gag p7和p6以及gag/pol多蛋白内蛋白酶切割位点的自然变异：无蛋白酶抑制剂情况下的氨基酸替代
Virology. 1996 May 15;219(2):407-16. doi: 10.1006/viro.1996.0266.
8
Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.HIV-1 B和G亚型中蛋白酶突变的基因型解释与表型作用不一致
J Antimicrob Chemother. 2009 Mar;63(3):593-9. doi: 10.1093/jac/dkn526. Epub 2009 Jan 10.
9
Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.对67名曾使用茚地那韦治疗的感染人类免疫缺陷病毒且患有艾滋病的患者，采用利托那韦/沙奎那韦联合用药方案进行前瞻性随访。
Clin Infect Dis. 1999 May;28(5):1184-5. doi: 10.1086/517781.
10
The choice of HIV protease inhibitor: indinavir is currently the best option.人类免疫缺陷病毒蛋白酶抑制剂的选择：茚地那韦目前是最佳选择。
Prescrire Int. 1999 Apr;8(40):55-60.
引用本文的文献
1
Cellular Targets of HIV-1 Protease: Just the Tip of the Iceberg?HIV-1 蛋白酶的细胞靶标：仅仅是冰山一角？
Viruses. 2023 Mar 9;15(3):712. doi: 10.3390/v15030712.
2
Effectively predicting HIV-1 protease cleavage sites by using an ensemble learning approach.利用集成学习方法有效预测 HIV-1 蛋白酶切割位点。
BMC Bioinformatics. 2022 Oct 27;23(1):447. doi: 10.1186/s12859-022-04999-y.
3
Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast ().裂殖酵母中的单药及固定剂量组合的HIV-1蛋白酶抑制剂药物（）
Pathogens. 2021 Jun 24;10(7):804. doi: 10.3390/pathogens10070804.
4
Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.在 HIV Gag 切割位点突变体和对现有药物类别具有耐药性的分离株中，未观察到 Lenacapavir（GS-6207）表型耐药性。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02057-20.
5
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.仅 HIV-1 Gag 突变就足以降低强化蛋白酶抑制剂治疗病毒学失败时对达芦那韦的敏感性。
J Antimicrob Chemother. 2020 Sep 1;75(9):2535-2546. doi: 10.1093/jac/dkaa228.
6
Pan-retroviral Nucleocapsid-Mediated Phase Separation Regulates Genomic RNA Positioning and Trafficking.全逆转录病毒核衣壳介导的相分离调节基因组RNA的定位和运输。
Cell Rep. 2020 Apr 21;31(3):107520. doi: 10.1016/j.celrep.2020.03.084.
7
Development of A Fission Yeast Cell-Based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.用于高通量筛选HIV-1蛋白酶抑制剂的基于裂殖酵母细胞的平台的开发
Curr HIV Res. 2019;17(6):429-440. doi: 10.2174/1570162X17666191128102839.
8
Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy.抗逆转录病毒治疗前后获得的 HIV-1 gag 和 gp41 配对序列的选择分析。
Sci Data. 2018 Jul 24;5:180147. doi: 10.1038/sdata.2018.147.
9
Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.喀麦隆雅温得地区感染 HIV-1 CRF02_AG 和非 CRF02_AG 的患者中 gag P2/NC 和 pol 基因多样性、多态性和耐药突变。
Sci Rep. 2017 Oct 26;7(1):14136. doi: 10.1038/s41598-017-14095-4.
10
Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.接受利托那韦增强蛋白酶抑制剂治疗的患者 gag 和 gp41 的进化。
Sci Rep. 2017 Sep 14;7(1):11559. doi: 10.1038/s41598-017-11893-8.
本文引用的文献
1
Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism.HIV-1蛋白酶前体的蛋白水解加工、动力学及机制
J Biol Chem. 1999 Aug 13;274(33):23437-42. doi: 10.1074/jbc.274.33.23437.
2
Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity.1型人类免疫缺陷病毒对蛋白酶抑制剂的耐药性对逆转录酶加工、活性及药物敏感性的影响
J Virol. 1999 Apr;73(4):3455-9. doi: 10.1128/JVI.73.4.3455-3459.1999.
3
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database.人类免疫缺陷病毒逆转录酶和蛋白酶序列数据库
Nucleic Acids Res. 1999 Jan 1;27(1):348-52. doi: 10.1093/nar/27.1.348.
4
Resistance to human immunodeficiency virus type 1 protease inhibitors.对1型人类免疫缺陷病毒蛋白酶抑制剂的耐药性。
Antimicrob Agents Chemother. 1998 Nov;42(11):2775-83. doi: 10.1128/AAC.42.11.2775.
5
Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.1型人类免疫缺陷病毒中与耐药相关的病毒适应性丧失：蛋白酶抑制剂治疗患者中蛋白酶与gag共同进化的表型分析
J Virol. 1998 Sep;72(9):7632-7. doi: 10.1128/JVI.72.9.7632-7637.1998.
6
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.对新型蛋白酶抑制剂ABT-378具有更高抗性的1型人类免疫缺陷病毒变体的体外筛选与特性分析
J Virol. 1998 Sep;72(9):7532-41. doi: 10.1128/JVI.72.9.7532-7541.1998.
7
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.成人HIV感染者的抗逆转录病毒药物耐药性检测：对临床管理的影响。国际艾滋病学会美国小组。
JAMA. 1998 Jun 24;279(24):1984-91. doi: 10.1001/jama.279.24.1984.
8
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.一种用于同时检测接受抗逆转录病毒药物治疗患者的重组人免疫缺陷病毒1型分离株中蛋白酶和逆转录酶抑制剂表型耐药性的快速方法。
Antimicrob Agents Chemother. 1998 Feb;42(2):269-76. doi: 10.1128/AAC.42.2.269.
9
Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.在体内选择出的对蛋白酶抑制剂具有抗性的1型人类免疫缺陷病毒变体中，与多种Gag和Gag - Pol加工缺陷相关的病毒适应性丧失。
J Virol. 1998 Apr;72(4):3300-6. doi: 10.1128/JVI.72.4.3300-3306.1998.
10
The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity.人类免疫缺陷病毒1型Nef的蛋白水解切割与其刺激病毒体感染性的能力不相关。
J Virol. 1998 Apr;72(4):3178-84. doi: 10.1128/JVI.72.4.3178-3184.1998.
Zotero 插件